Crispr Therapeutics, Vertex Get FDA Approval for Breakthrough Gene-editing Treatment
Crispr Therapeutics, Vertex Get FDA Approval for Breakthrough Gene-editing Treatment
Crispr Therapeutics、Vertex 獲得美國食品藥品管理局批准進行突破性基因編輯
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊